Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604010467> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2604010467 endingPage "e13582" @default.
- W2604010467 startingPage "e13582" @default.
- W2604010467 abstract "e13582 Background: An AD regimen of 37.5mg daily in repeated 4-weeks on, 2-weeks off cycle has been proposed to ameliorate frequent dose modifications due to toxicities as observed with the approved dosing regimen of sunitinib for mRCC. This study aims to determine the effect of drug exposure (sunitinib and active metabolite, SU12662) on clinical response and toxicities in patients receiving this AD regimen. Methods: All mRCC patients starting on sunitinib were invited to participate in this study. In week 4 of each cycle, toxicities were assessed and graded according to CTCAE and plasma AUC ss was quantified using high-performance liquid chromatography. Clinical response was assessed after 2 treatment cycles; and was used with drug exposure and toxicities data for dose adjustments. Statistical tests such as Mann-Whitney U were used to compare the levels between groups. Results: 24 patients with a mean age of 58.8 ± 11.2 years were recruited. Majority were males (75%) and Chinese (87.5%). Among the 17 and 14 analyzable cases for cycle 1 and 2, median total AUC ss were 2.2 and 2.1 µg•h/ml respectively. Fourteen patients completed 2 treatment cycles; 7 (50%) partial response, 4 (28.6%)stable disease and 3 (21.4%) progressive disease. A dose increment to 50mg daily was performed for a patient with disease progression. Common grade 2 and above toxicities were hypertension, hand foot syndrome (HFS) and mucositis. Higher drug exposures were observed among patients who achieved clinical responseand among those who experienced at least grade 2 toxicities. Conclusions: Drug exposure could likely be associated with clinical response and toxicities in this AD regimen. [Table: see text]" @default.
- W2604010467 created "2017-04-07" @default.
- W2604010467 creator A5024654014 @default.
- W2604010467 creator A5029422899 @default.
- W2604010467 creator A5036351512 @default.
- W2604010467 creator A5037495975 @default.
- W2604010467 creator A5060981830 @default.
- W2604010467 creator A5076398158 @default.
- W2604010467 creator A5080867207 @default.
- W2604010467 creator A5081294763 @default.
- W2604010467 date "2013-05-20" @default.
- W2604010467 modified "2023-10-14" @default.
- W2604010467 title "Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib." @default.
- W2604010467 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e13582" @default.
- W2604010467 hasPublicationYear "2013" @default.
- W2604010467 type Work @default.
- W2604010467 sameAs 2604010467 @default.
- W2604010467 citedByCount "1" @default.
- W2604010467 countsByYear W26040104672020 @default.
- W2604010467 crossrefType "journal-article" @default.
- W2604010467 hasAuthorship W2604010467A5024654014 @default.
- W2604010467 hasAuthorship W2604010467A5029422899 @default.
- W2604010467 hasAuthorship W2604010467A5036351512 @default.
- W2604010467 hasAuthorship W2604010467A5037495975 @default.
- W2604010467 hasAuthorship W2604010467A5060981830 @default.
- W2604010467 hasAuthorship W2604010467A5076398158 @default.
- W2604010467 hasAuthorship W2604010467A5080867207 @default.
- W2604010467 hasAuthorship W2604010467A5081294763 @default.
- W2604010467 hasConcept C112705442 @default.
- W2604010467 hasConcept C126322002 @default.
- W2604010467 hasConcept C2776694085 @default.
- W2604010467 hasConcept C2777288759 @default.
- W2604010467 hasConcept C2777472916 @default.
- W2604010467 hasConcept C2778496288 @default.
- W2604010467 hasConcept C2778822529 @default.
- W2604010467 hasConcept C2779490328 @default.
- W2604010467 hasConcept C2781413609 @default.
- W2604010467 hasConcept C29730261 @default.
- W2604010467 hasConcept C71924100 @default.
- W2604010467 hasConcept C90924648 @default.
- W2604010467 hasConcept C98274493 @default.
- W2604010467 hasConceptScore W2604010467C112705442 @default.
- W2604010467 hasConceptScore W2604010467C126322002 @default.
- W2604010467 hasConceptScore W2604010467C2776694085 @default.
- W2604010467 hasConceptScore W2604010467C2777288759 @default.
- W2604010467 hasConceptScore W2604010467C2777472916 @default.
- W2604010467 hasConceptScore W2604010467C2778496288 @default.
- W2604010467 hasConceptScore W2604010467C2778822529 @default.
- W2604010467 hasConceptScore W2604010467C2779490328 @default.
- W2604010467 hasConceptScore W2604010467C2781413609 @default.
- W2604010467 hasConceptScore W2604010467C29730261 @default.
- W2604010467 hasConceptScore W2604010467C71924100 @default.
- W2604010467 hasConceptScore W2604010467C90924648 @default.
- W2604010467 hasConceptScore W2604010467C98274493 @default.
- W2604010467 hasIssue "15_suppl" @default.
- W2604010467 hasLocation W26040104671 @default.
- W2604010467 hasOpenAccess W2604010467 @default.
- W2604010467 hasPrimaryLocation W26040104671 @default.
- W2604010467 hasRelatedWork W2004325424 @default.
- W2604010467 hasRelatedWork W2056402925 @default.
- W2604010467 hasRelatedWork W2072245035 @default.
- W2604010467 hasRelatedWork W2171237277 @default.
- W2604010467 hasRelatedWork W2367626691 @default.
- W2604010467 hasRelatedWork W2544140097 @default.
- W2604010467 hasRelatedWork W2564759327 @default.
- W2604010467 hasRelatedWork W2587843034 @default.
- W2604010467 hasRelatedWork W3151554875 @default.
- W2604010467 hasRelatedWork W4205243027 @default.
- W2604010467 hasVolume "31" @default.
- W2604010467 isParatext "false" @default.
- W2604010467 isRetracted "false" @default.
- W2604010467 magId "2604010467" @default.
- W2604010467 workType "article" @default.